Evotec SE (NASDAQ:EVO) Sees Significant Increase in Short Interest

Evotec SE (NASDAQ:EVO - Get Free Report) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 766,200 shares, a growth of 89.9% from the December 31st total of 403,500 shares. Approximately 0.3% of the company's shares are short sold. Based on an average daily volume of 232,100 shares, the short-interest ratio is presently 3.3 days.

Evotec Stock Performance

Shares of NASDAQ EVO traded up $0.03 on Friday, reaching $4.52. 144,191 shares of the company's stock traded hands, compared to its average volume of 47,320. The business's 50 day simple moving average is $4.47 and its two-hundred day simple moving average is $4.04. Evotec has a 12 month low of $2.85 and a 12 month high of $7.98. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Evotec during the second quarter valued at approximately $87,000. Clear Harbor Asset Management LLC purchased a new stake in Evotec during the 3rd quarter valued at $104,000. Mediolanum International Funds Ltd bought a new stake in shares of Evotec in the 3rd quarter worth $512,000. Finally, Wellington Management Group LLP increased its holdings in shares of Evotec by 29.7% in the 3rd quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company's stock worth $9,616,000 after purchasing an additional 602,858 shares in the last quarter. Institutional investors own 5.81% of the company's stock.

Wall Street Analyst Weigh In

EVO has been the subject of several research reports. HC Wainwright reissued a "buy" rating and issued a $8.00 target price on shares of Evotec in a research report on Thursday, November 7th. Jefferies Financial Group downgraded Evotec from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $8.70 to $3.80 in a report on Monday, October 7th.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.